ライフサイエンスコーパス: trimethoprim-sulfamethoxazole

1 tracycline, ormetoprim-sulfadimethoxine, and trimethoprim-sulfamethoxazole).

2 at Y. pestis, except for chloramphenicol and trimethoprim-sulfamethoxazole.

3 ompared by testing 567 staphylococci against trimethoprim-sulfamethoxazole.

4 e mice also received antibiotic therapy with trimethoprim-sulfamethoxazole.

5 0-day outpatient course of ciprofloxacin and trimethoprim-sulfamethoxazole.

6 lls/microL, despite anti-Pc prophylaxis with trimethoprim-sulfamethoxazole.

7 penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole.

8 All infants also received high-dose trimethoprim-sulfamethoxazole.

9 osporins, fluoroquinolones, penicillins, and trimethoprim-sulfamethoxazole.

10 acin, gentamicin, rifampin, minocycline, and trimethoprim-sulfamethoxazole.

11 ftriaxone, ciprofloxacin, gentamicin, and/or trimethoprim-sulfamethoxazole.

12 penicillin, and 57 (82.6%) were resistant to trimethoprim-sulfamethoxazole.

13 a penicillin or macrolide antibiotic, or for trimethoprim-sulfamethoxazole.

14 or aadA and dhfr, which confer resistance to trimethoprim-sulfamethoxazole.

15 profloxacin, and only 7% were susceptible to trimethoprim-sulfamethoxazole.

16 mbination with ampicillin, trimethoprim, and trimethoprim-sulfamethoxazole.

17 caused by E. coli strains with resistance to trimethoprim-sulfamethoxazole.

18 rrhea ceased in all 19 patients treated with trimethoprim-sulfamethoxazole.

19 acycline, chloramphenicol, erythromycin, and trimethoprim-sulfamethoxazole.

20 acceptable for patients who cannot tolerate trimethoprim-sulfamethoxazole.

21 n, aztreonam, erythromycin, clindamycin, and trimethoprim-sulfamethoxazole.

22 reptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole.

23 f resistances to beta-lactam antibiotics and trimethoprim-sulfamethoxazole.

24 s, and prior receipt of ciprofloxacin and/or trimethoprim-sulfamethoxazole.

25 esistant to nalidixic acid, cephalothin, and trimethoprim-sulfamethoxazole.

26 and ganciclovir, and lack of prescription of trimethoprim-sulfamethoxazole.

27 penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole.

28 mmunodeficiency virus who could not tolerate trimethoprim-sulfamethoxazole.

29 tetracycline, gentamicin, ciprofloxacin, and trimethoprim-sulfamethoxazole.

30 in, erythromycin, imipenem, minocycline, and trimethoprim-sulfamethoxazole.

31 o penicillin, 12% to ceftazidime, and 24% to trimethoprim-sulfamethoxazole.

32 cies are interpreted based on human data for trimethoprim-sulfamethoxazole.

33 ycycline, 29.7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole.

34 ciprofloxacin, clindamycin, gentamicin, and trimethoprim-sulfamethoxazole.

35 oxacin, clindamycin, gentamicin sulfate, and trimethoprim-sulfamethoxazole.

36 olid, minocyline, tigecycline, rifampin, and trimethoprim/sulfamethoxazole.

37 ime (1 of 209, 0.5%), and mixed species with trimethoprim-sulfamethoxazole (1 of 366, 0.3%).

38 Intermediate resistance was detected for trimethoprim-sulfamethoxazole (10 strains) and clindamyc

39 ients were randomly assigned to receive oral trimethoprim-sulfamethoxazole (160 mg or 800 mg) or cipr

40 Trimethoprim-sulfamethoxazole (160/800 mg twice daily fo

41 for 7 days (n = 128 included in analysis) vs trimethoprim-sulfamethoxazole, 160/800 mg twice per day

42 and, to a lesser extent, to kanamycin (19%), trimethoprim-sulfamethoxazole (17%), and gentamicin (11%

43 infections, was more frequently resistant to trimethoprim-sulfamethoxazole (18%) than to ciprofloxaci

44 Cephalexin, 500 mg 4 times daily, plus trimethoprim-sulfamethoxazole, 320 mg/1600 mg twice dail

45 y selected isolates that were susceptible to trimethoprim-sulfamethoxazole (4 percent, P<0.001).

46 esistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole; 4 were also resistant to

47 ), ethambutol (92%), and sulfamethoxazole or trimethoprim-sulfamethoxazole (70%).

48 solate combinations and overall was best for trimethoprim-sulfamethoxazole (75% for one isolate and 1

49 onsusceptible to penicillin, macrolides, and trimethoprim-sulfamethoxazole, 8 had other resistance pa

50 ythromycin (73.9%), clindamycin (65.5%), and trimethoprim-sulfamethoxazole (80%); however, categorica

51 were successfully treated in all cases using trimethoprim-sulfamethoxazole (800 mg/160 mg) twice dail

52 with sufficient on-scale MICs occurred with trimethoprim-sulfamethoxazole (89.7%).

53 n, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%.

54 ence implementing a protocolized approach to trimethoprim-sulfamethoxazole adverse drug reaction asse

55 Forty-two patients (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions doc

56 zole, as compared with standard prophylaxis (trimethoprim-sulfamethoxazole alone).

57 While the prevalence of resistance to trimethoprim-sulfamethoxazole, ampicillin, and cephaloth

58 occus spp. had high MICs of >4/76 mug/ml for trimethoprim-sulfamethoxazole, an antibiotic commonly us

59 micin, and tobramycin; 96% were resistant to trimethoprim-sulfamethoxazole and 41% to ciprofloxacin h

60 Of the EAggEc strains, 51% were resistant to trimethoprim-sulfamethoxazole and 65% were resistant to

61 cycline (100% for all isolates), followed by trimethoprim-sulfamethoxazole and ciprofloxacin.

62 showed that all strains were susceptible to trimethoprim-sulfamethoxazole and ciprofloxacin.

63 With trimethoprim-sulfamethoxazole and fluoroquinolones, the

64 icillin, imipenem, gentamicin, amikacin, and trimethoprim-sulfamethoxazole and had reduced susceptibi

65 lates which were resistant to penicillin and trimethoprim-sulfamethoxazole and had the molecular prop

66 Trimethoprim-sulfamethoxazole and macrolide use were not

67 up showed a trend of increased resistance to trimethoprim-sulfamethoxazole and nitrofurantoin, it was

68 was 0 of 46 (0%) and 6 of 47 (12.80%) in the trimethoprim-sulfamethoxazole and placebo groups, respec

69 ted in vivo by treatment with the antibiotic trimethoprim-sulfamethoxazole and possibly by coinfectio

70 nt E coli; prior receipt of ciprofloxacin or trimethoprim-sulfamethoxazole and presence of a gastrost

71 boratory interpretation of in vitro MICs for trimethoprim-sulfamethoxazole and sulfamethoxazole and t

72 Additional prophylaxis included trimethoprim-sulfamethoxazole and valganciclovir.

73 th resistance to ampicillin, gentamicin, and trimethoprim-sulfamethoxazole and with susceptibility to

74 solates were found to have resistant MICs of trimethoprim-sulfamethoxazole and/or sulfamethoxazole.

75 tudy support a single breakpoint for testing trimethoprim-sulfamethoxazole and/or trimethoprim-sulfad

76 and levofloxacin among S. pneumoniae and for trimethoprim/sulfamethoxazole and azithromycin among H.

77 %) were resistant to ampicillin, 35 (90%) to trimethoprim-sulfamethoxazole, and 24 (62%) to chloramph

78 luoroquinolones, 100 percent to rifampin and trimethoprim-sulfamethoxazole, and 92 percent to tetracy

79 pregnant women who received bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretro

80 ant women with HIV receiving bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretro

81 e PBP genes, and resistance to tetracycline, trimethoprim-sulfamethoxazole, and erythromycin, and the

82 lity to ceftiofur, erythromycin, tilmicosin, trimethoprim-sulfamethoxazole, and florfenicol, with som

83 to carbapenems but susceptible to aztreonam, trimethoprim-sulfamethoxazole, and fluoroquinolones.

84 -MRSA is usually susceptible to clindamycin, trimethoprim-sulfamethoxazole, and rifampin, but inducib

85 es were susceptible in vitro to clindamycin, trimethoprim-sulfamethoxazole, and rifampin.

86 penem, penicillin (PEN), tetracycline (TET), trimethoprim-sulfamethoxazole, and vancomycin.

87 ropenem, penicillin, rifampin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin.

88 ttransplant therapy consisted of tacrolimus, trimethoprim/sulfamethoxazole, and prednisone (the latte

89 effect of aminopenicillin, fluoroquinolone, trimethoprim/sulfamethoxazole, and tetracycline usage on

90 As adjuvant therapy, trimethoprim-sulfamethoxazole appears to be useful in pr

91 nded-spectrum penicillins, tetracycline, and trimethoprim-sulfamethoxazole are good treatment options

92 lfadiazine with S. equi This study indicates trimethoprim-sulfamethoxazole as an acceptable surrogate

93 from the California cohort were resistant to trimethoprim-sulfamethoxazole as well as other antibioti

94 . emergency departments to determine whether trimethoprim-sulfamethoxazole (at doses of 320 mg and 16

95 Among patients who cannot tolerate trimethoprim-sulfamethoxazole, atovaquone and dapsone ar

96 B. pertussis for resistance to erythromycin, trimethoprim-sulfamethoxazole, chloramphenicol, and rifa

97 Trimethoprim-sulfamethoxazole, ciprofloxacin, and pipera

98 d for the following agents: chloramphenicol, trimethoprim-sulfamethoxazole, ciprofloxacin, and rifamp

99 venous vancomycin followed by 1 week of oral trimethoprim-sulfamethoxazole combination therapy.

100 cated cellulitis, the use of cephalexin plus trimethoprim-sulfamethoxazole compared to cephalexin alo

101 ne and of presumed bacterial infections with trimethoprim/sulfamethoxazole (cotrimoxazole) was assess

102 Current antiretroviral therapy or use of trimethoprim-sulfamethoxazole did not impact the risk of

103 al catheter plus treatment with rifampin and trimethoprim-sulfamethoxazole eradicated the infection.

104 Prophylaxis for PCP and toxoplasmosis with trimethoprim-sulfamethoxazole for patients with CD4 cell

105 n of E. coli isolates that were resistant to trimethoprim-sulfamethoxazole from women with community-

106 romycin (from 11 percent to 16 percent), and trimethoprim-sulfamethoxazole (from 25 percent to 29 per

107 mportant difference favoring cephalexin plus trimethoprim-sulfamethoxazole, further research may be n

108 l agents, including ampicillin, ceftazidime, trimethoprim-sulfamethoxazole, gentamicin, and ciproflox

109 the ESBL TEM-10, and mediated resistance to trimethoprim-sulfamethoxazole, gentamicin, and tobramyci

110 24-month visit for 428 children (214 in the trimethoprim-sulfamethoxazole group and 214 in the place

111 loped in 2 of 524 participants (0.4%) in the trimethoprim-sulfamethoxazole group and in 2 of 533 part

112 Weight gain in the trimethoprim-sulfamethoxazole group and the placebo grou

113 ed in 507 of 630 participants (80.5%) in the trimethoprim-sulfamethoxazole group versus 454 of 617 pa

114 ed in 487 of 524 participants (92.9%) in the trimethoprim-sulfamethoxazole group versus 457 of 533 pa

115 ) of 218 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 165 (85.5%) of 19

116 ) of 248 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 171 (69.0%) of 24

117 had developed in 1 participant (0.2%) in the trimethoprim-sulfamethoxazole group.

118 entioned in 38 case reports, gold in 11, and trimethoprim-sulfamethoxazole in 10.

119 to sulfisoxazole in 21.7% of strains and to trimethoprim-sulfamethoxazole in 21.0% resulted from pol

120 s of isoniazid-pyridoxine (coformulated with trimethoprim-sulfamethoxazole in a single fixed-dose com

121 , clarithromycin, doxycycline, imipenem, and trimethoprim-sulfamethoxazole in each of four laboratori

122 Resistance to trimethoprim-sulfamethoxazole in Iran is low and this dr

123 ates the utility of prolonged treatment with trimethoprim-sulfamethoxazole in Nocardia infections.

124 While trimethoprim-sulfamethoxazole is considered first-line t

125 A 1-week course of trimethoprim-sulfamethoxazole is effective in HIV-infect

126 Although trimethoprim-sulfamethoxazole is the drug of choice for

127 Trimethoprim-sulfamethoxazole is the preferred drug regi

128 and treatment of Pneumocystis pneumonia with trimethoprim/sulfamethoxazole is effective in reducing t

129 lumefantrine exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is

130 inum isolates to be as follows (rank order): trimethoprim-sulfamethoxazole (MIC at which 90% of the i

131 ry concentration, >/=1 microg/mL) and 19% to trimethoprim/sulfamethoxazole (minimal inhibitory concen

132 to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]

133 esistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant S. Ty

134 , including ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant Salmo

135 d accounted for >/=40% (beta-lactams), >50% (trimethoprim-sulfamethoxazole , multidrug), or >70% (cip

136 Immediate antimicrobial therapy with trimethoprim-sulfamethoxazole, nitrofurantoin, or fosfom

137 ce interval (CI), 0.60-0.97; P =.03; risk of trimethoprim-sulfamethoxazole nonsusceptibility was also

138 Trimethoprim-sulfamethoxazole or methotrexate may be val

139 Trimethoprim-sulfamethoxazole or placebo taken orally, o

140 Additionally, each was randomized to trimethoprim-sulfamethoxazole or placebo.

141 P = 0.016) and less frequently resistant to trimethoprim-sulfamethoxazole (OR = 0.38; 95% CI = 0.18

142 cases were treated with other beta-lactams, trimethoprim-sulfamethoxazole, or vancomycin.

143 ce to amoxicillin-clavulanic acid (P = .03), trimethoprim-sulfamethoxazole (P = .01), and ciprofloxac

144 .002), and to cephalothin, trimethoprim, and trimethoprim-sulfamethoxazole (P<.001).

145 ted CAS, the most common antimicrobials were trimethoprim-sulfamethoxazole, penicillin, and amoxicill

146 l prophylaxis, which consisted of continuous trimethoprim-sulfamethoxazole plus at least 12 weeks of

147 Trimethoprim-sulfamethoxazole promotes the excision of a

148 nomic outcomes associated with no treatment, trimethoprim-sulfamethoxazole prophylaxis alone, antiret

149 ting and clinical criteria, as compared with trimethoprim-sulfamethoxazole prophylaxis alone.

150 A strategy of trimethoprim-sulfamethoxazole prophylaxis and antiretrov

151 Women received daily trimethoprim-sulfamethoxazole prophylaxis and insecticid

152 uster, which was controlled after systematic trimethoprim-sulfamethoxazole prophylaxis in exposed pat

153 ract infection, we evaluated the efficacy of trimethoprim-sulfamethoxazole prophylaxis in preventing

154 Trimethoprim-sulfamethoxazole prophylaxis resulted in sa

155 , and no further cases were identified after trimethoprim-sulfamethoxazole prophylaxis was introduced

156 lysis of data from a large clinical trial of trimethoprim-sulfamethoxazole prophylaxis, there was no

157 re as cost-effective as those that also used trimethoprim-sulfamethoxazole prophylaxis.

158 Trimethoprim/sulfamethoxazole prophylaxis was associated

159 Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered

160 loxacin, rifampin, parenteral gentamicin, or trimethoprim-sulfamethoxazole provide the best therapeut

161 Significantly more patients underwent trimethoprim-sulfamethoxazole rechallenge after protocol

162 The introduction of a standard approach to trimethoprim-sulfamethoxazole rechallenge in the context

163 floxacin regimen and 83% (92 of 111) for the trimethoprim-sulfamethoxazole regimen (95% CI, 0.06-0.22

164 floxacin regimen and 89% (90 of 101) for the trimethoprim-sulfamethoxazole regimen (95% confidence in

165 ologic and clinical cure rates than a 14-day trimethoprim-sulfamethoxazole regimen, especially in pat

166 atients receiving secondary prophylaxis with trimethoprim-sulfamethoxazole remained disease-free, and

167 ting P carinii pneumonia; the combination of trimethoprim-sulfamethoxazole remains the first-line age

168 (clonal group A), in 28 of 55 isolates with trimethoprim-sulfamethoxazole resistance (51 percent) an

169 foreign travel significantly predicted both trimethoprim-sulfamethoxazole resistance (prevalence rat

170 cently recognized significant contributor to trimethoprim-sulfamethoxazole resistance in the United S

171 cible clindamycin resistance (ICR) (n = 30), trimethoprim-sulfamethoxazole-resistant MRSA (n = 10), v

172 egimen, especially in patients infected with trimethoprim-sulfamethoxazole-resistant strains.

173 f isolates were resistant to clindamycin and trimethoprim/sulfamethoxazole, respectively.

174 Cefprozil, cefaclor, and trimethoprim-sulfamethoxazole results differed the most,

175 of the four antimicrobial agents tested; the trimethoprim-sulfamethoxazole results were lower with Et

176 Trimethoprim-sulfamethoxazole retains clinical efficacy,

177 prevalence of resistance to trimethoprim and trimethoprim-sulfamethoxazole rose from more than 9% in

178 Patients treated with standard-dose trimethoprim-sulfamethoxazole should be monitored closel

179 of travel-associated infections resistant to trimethoprim-sulfamethoxazole, sulfisoxazole, streptomyc

180 isolates (112 of 120) were also resistant to trimethoprim-sulfamethoxazole (SXT) (97 of 120 isolates,

181 Ten days of trimethoprim-sulfamethoxazole (SXT) therapy reduces urin

182 Overall ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (SXT), and cefazolin (CFZ)

183 us urinae has been described as resistant to trimethoprim-sulfamethoxazole (SXT), but the test medium

184 maining patients were randomized to Group 1 (trimethoprim/sulfamethoxazole tablet every 2 days) or Gr

185 e acceptable for all drugs tested except for trimethoprim-sulfamethoxazole testing by the Etest.

186 and cyclosporiasis ceased more rapidly with trimethoprim-sulfamethoxazole than with ciprofloxacin.

187 However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent par

188 Standard-dose trimethoprim-sulfamethoxazole therapy used to treat vari

189 1.09 to 1.32 mmol/L) 4.6 +/- 2.2 days after trimethoprim-sulfamethoxazole therapy was initiated.

190 Trimethoprim/sulfamethoxazole therapy resulted in a 100%

191 drug (27%), followed by phosphomycin (23%), trimethoprim-sulfamethoxazole (TMP-SMX) (9%), and cefuro

192 Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinol

193 Daily trimethoprim-sulfamethoxazole (TMP-SMX) and insecticide-

194 Long-term antibiotic therapy included oral trimethoprim-sulfamethoxazole (TMP-SMX) and rifampin, TM

195 Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly pre

196 a 1:1 ratio to receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days.

197 drugs like HIV protease inhibitors (PIs) and trimethoprim-sulfamethoxazole (TMP-SMX) have known activ

198 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used f

199 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used i

200 44) or HIV exposed (n = 175) and prescribed trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

201 up to 42 days, primarily in those receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

202 Late in the course of this trial, trimethoprim-sulfamethoxazole (TMP-SMX) was incorporated

203 lin, 649 (58%) to streptomycin, 402 (36%) to trimethoprim-sulfamethoxazole (TMP-SMX), 355 (32%) to su

204 in, 19 isolates (43%) were nonsusceptible to trimethoprim-sulfamethoxazole (TMP-SMX), and all isolate

205 amikacin, ciprofloxacin, imipenem, rifampin, trimethoprim-sulfamethoxazole (TMP-SMX), and vancomycin.

206 re randomly assigned to receive clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or placebo for

207 ortant has been the increasing resistance to trimethoprim-sulfamethoxazole (TMP-SMX), the current dru

208 Additionally, trimethoprim-sulfamethoxazole (TMP-SMX), used for opport

209 of urinary tract infections (UTI) caused by trimethoprim-sulfamethoxazole (TMP-SMX)-resistant Escher

210 Trimethoprim-sulfamethoxazole (TMP-SMZ) is an alternativ

211 Trimethoprim-sulfamethoxazole (TMP-SMZ) is the most effe

212 han other adults, and many receive long-term trimethoprim-sulfamethoxazole (TMP-SMZ) prophylactic the

213 were less likely than controls to have used trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis (odd

214 these organisms is typically susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ), and this theref

215 The efficacy of trimethoprim-sulfamethoxazole (TMP/SMX) in the preventio

216 While antifolates such as Bactrim (trimethoprim-sulfamethoxazole; TMP-SMX) continue to play

217 is, controlled either with no prophylaxis or trimethoprim/sulfamethoxazole (TMS) prophylaxis.

218 cellulitis without abscess, the addition of trimethoprim-sulfamethoxazole to cephalexin did not impr

219 Among trimethoprim-sulfamethoxazole-treated patients, drug res

220 ofloxacin-treated patients and in 33% of 187 trimethoprim-sulfamethoxazole-treated patients, respecti

221 In settings in which MRSA was prevalent, trimethoprim-sulfamethoxazole treatment resulted in a hi

222 Eighty patients treated with standard-dose trimethoprim-sulfamethoxazole (trimethoprim, < or = 320

223 onthly sulfadoxine-pyrimethamine (SP), daily trimethoprim-sulfamethoxazole (TS), or monthly dihydroar

224 0.002) for M. avium complex bacteremia, and trimethoprim-sulfamethoxazole use was associated with de

225 were sensitive to minocycline, doxycycline, trimethoprim-sulfamethoxazole, vancomycin, teicoplanin,

226 roportion of isolates that were resistant to trimethoprim-sulfamethoxazole was 63% in the prophylaxis

227 Trimethoprim-sulfamethoxazole was associated with slight

228 Resistance to trimethoprim-sulfamethoxazole was significantly higher a

229 Trimethoprim-sulfamethoxazole was superior to placebo wi

230 em, levofloxacin, meropenem, tobramycin, and trimethoprim-sulfamethoxazole were comparable for the tw

231 n, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazole were determined for each i

232 and N. otitidiscaviarum were susceptible to trimethoprim-sulfamethoxazole, while 8% of N. farcinica

233 Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood

234 Prophylaxis most frequently involves trimethoprim-sulfamethoxazole, with second-line therapie

235 To determine whether cephalexin plus trimethoprim-sulfamethoxazole yields a higher clinical c